Compare CWBC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CWBC | NMRA |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | United States | United States |
| Employees | 341 | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.6M | 554.0M |
| IPO Year | N/A | 2023 |
| Metric | CWBC | NMRA |
|---|---|---|
| Price | $24.20 | $2.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $28.00 | $7.50 |
| AVG Volume (30 Days) | 159.4K | ★ 1.2M |
| Earning Date | 04-17-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.58 | N/A |
| Revenue Next Year | $17.64 | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.03 | $0.63 |
| 52 Week High | $25.72 | $3.65 |
| Indicator | CWBC | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 33.77 |
| Support Level | $22.02 | $1.79 |
| Resistance Level | $24.77 | $2.20 |
| Average True Range (ATR) | 0.41 | 0.16 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 93.75 | 22.64 |
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments. The company has one reportable segment: Banking operations. Loans and leases, investment securities, interest-bearing deposits and non-interest income provide the revenues of the banking operation.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.